根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在2024年1月份 J.P. MORGAN HEALTHC...
根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在2024年1月份 J.P. MORGAN HEALTHC...
1、https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-548-treatment. 2、《“3亿疼痛患者,4000亿市场”,一文深度了解止痛药行业》头豹,?2023-11-17. 3、https://www.orion.fi/en/...
根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在2024年1月份 J.P. MORGAN HEALTHC...
METHODSAfter establishing the selectivity of VX-548 forNaV1.8inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, participants were randomly assigned in a 1:1:1:1 ratio to receive one of th...
该申请得到了两项Phase III研究结果的支持,这两项研究分别涉及1118名和1073名在腹部整形手术和拇外翻矫正术后经历中度至重度疼痛的患者。结果显示,尽管suzetrigine在减轻疼痛强度方面优于安慰剂,但未能显示出优于氢可酮比沙星/对乙酰氨基酚组合的效果。尽管结果混杂,首席医疗官Carmen Bozic当时表示,由于该药物在整个项...
Voltage-gated sodium channels (VGSCs) play an important role in action potential generation and propagation and mediate the rapid influx of sodium ions that underlies the rising phase of the action potential in sensory nociceptive neurons (Blair and Bean
-VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiatein Q42022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - ...
- VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - ...
VX-548 Phase 3 Results in Patients Undergoing Bunionectomy Efficacy Results Patients aged 18 to 80 years with moderate or severe pain after bunionectomy surgery were eligible to participate in the trial. 1,073 patients were randomized and dosed with either VX-548 administered orally with an...